Unique ID issued by UMIN | UMIN000026571 |
---|---|
Receipt number | R000030509 |
Scientific Title | Efficacy test of the moisturizer SIR |
Date of disclosure of the study information | 2017/03/28 |
Last modified on | 2019/03/25 16:14:50 |
Efficacy test of the moisturizer SIR
Efficacy test of the moisturizer SIR
Efficacy test of the moisturizer SIR
Efficacy test of the moisturizer SIR
North America |
Healthy adults
Dermatology | Adult |
Others
NO
To confirm the moisturizing activity and the mechanism of the active ingredient for healthy skin
Efficacy
Change of water content, transepidermal water loss, visual score and texture before and after the topical application for 2, 4 and 5weeks
Change of cell morphology and the composition of stratum corneum before and after the topical application for 2, 4 and 5weeks
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Other |
Apply the formulation including an active ingredient to the one lower leg and the placebo to other lower leg twice daily for 4 weeks
20 | years-old | <= |
70 | years-old | >= |
Female
Healthy females
-Subjects with allergy for the skin care product
-Subjects who are pregnant, planning a pregnancy, or breastfeeding
- Subjects with a history of skin cancer, having active skin cancer, or who are receiving anti-cancer immunosuppressive treatments or medications
-Subjects with a history of immunosuppression/immune deficiency disorders (including (HIV infection or AIDS) or currently using immunosuppressive medications and/or radiation as determined by study documentation One with the plan to receive a medical act during study period
-Subjects currently participating in, or scheduled to participate in, any medical trial, consumer study, or any other clinical study on the body during the study period.
-Subjects who has caused abnormalities in the test site in a past similar study
-Subjects who takes hormone replacement therapy, or are on hormonal birth control
-Subjects who takes medical supplies (insulin, steroid, immunosuppressive drug) which may have an influence on the results
-Subjects deemed inappropriate to participate in this study by the principle investigator
25
1st name | |
Middle name | |
Last name | Takatoshi Murase |
Kao Corporation
R&D -Core Technology-Biological Science Research
2606 Akabane, Ichikai-Machi, Haga-Gun, TOCHIGI, 321-3497, JAPAN
0285-68-2963
murase.takatoshi@kao.co.jp
1st name | |
Middle name | |
Last name | Takatoshi Murase |
Kao Corporation
R&D -Core Technology-Biological Science Research
2606 Akabane, Ichikai-Machi, Haga-Gun, TOCHIGI, 321-3497, JAPAN
0285-68-2963
murase.takatoshi@kao.co.jp
Kao Corporation
Kao Corporation
Profit organization
Comprehensive Research Group
NO
Comprehensive Research Group(USA)
2017 | Year | 03 | Month | 28 | Day |
Unpublished
Completed
2017 | Year | 03 | Month | 10 | Day |
2017 | Year | 03 | Month | 10 | Day |
2017 | Year | 03 | Month | 29 | Day |
2018 | Year | 12 | Month | 31 | Day |
2017 | Year | 03 | Month | 15 | Day |
2019 | Year | 03 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030509
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |